Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Trial Profile

A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hafnium oxide (Primary) ; Nivolumab; Pembrolizumab
  • Indications Bladder cancer; Cancer metastases; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Liver metastases; Lung cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Nanobiotix
  • Most Recent Events

    • 05 Dec 2023 Planned End Date changed from 30 Mar 2028 to 30 May 2028.
    • 26 Sep 2023 According to a Nanobiotix media release, Phase 1 data update anticipated between 2H 2023 and 1H 2024.
    • 26 Sep 2023 According to a Nanobiotix media release, initial Phase 1 dose escalation safety data in pancreatic cancer from ongoing collaboration with MD Anderson is expected before the end of this year.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top